Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000–2020 French Cohort
by
, , ,
Clemence Basse
1,2
,
Matthieu Carton
3,
Maud Milder
4,
Romain Geiss
1,
Pauline Du Rusquec
1,
Catherine Daniel
1,
Marie-Ange Massiani
1,
Alain Livartowski
1,4 and
Nicolas Girard
1,2,* 1
Thoracic Oncology, Hôpital Institut Curie, St Cloud, 75005 Paris, France
2
Paris Saclay Campus, University Versailles Saint Quentin, 78035 Versailles, France
3
Biostatistic Department, Hôpital Institut Curie, St Cloud, 75005 Paris, France
4
Data Department, Hôpital Institut Curie, St Cloud, 75005 Paris, France
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(15), 2768; https://doi.org/10.3390/cancers16152768
Submission received: 15 June 2024
/
Revised: 31 July 2024
/
Accepted: 1 August 2024
/
Published: 5 August 2024
(This article belongs to the Special Issue Recent Advances in Trachea, Bronchus and Lung Cancer Management)
Simple Summary
The prognosis of metastatic lung cancer has been largely modified with targeted therapies and immunotherapies. Whether this survival benefit for subgroups of patients is beneficial to all patients treated for lung cancer has never been explored. The Institut Curie is an anti-cancer center in Paris, France, treating patients with lung cancer. Since the 2000s, Institut Curie has implemented dematerialized medical records, allowing for a large overview of the survival of patients with lung cancer according to treatment evolution. We found that the survival of patients with metastatic lung cancer has improved over the past 20 years, mostly in NSCLC (non-small cell lung cancer) but not in SCLC (small cell lung cancer). SCLC remains a disease with poor prognosis for which novel therapies are needed.
Abstract
Over the past 20 years, several innovative therapies have been implemented in the treatment of lung cancer that have had reported survival benefits in clinical trials. Whether these improvements translate into the clinic setting has not been studied yet. We retrospectively analyzed all patients consecutively treated at Institute Curie for metastatic lung cancer. Diagnosis date was used to define three periods, based on the approvals of novel treatment strategies in the first-line setting, including targeted therapies in 2010 and immunotherapy in 2018. Endpoints included Overall survival (OS), survival rate of 2 years and 5 years, and a conditional survival rate of 2 years (if still alive at 6 months from treatment initiation). A total of 673 patients were identified for Period 1—2000 to 2009, 752 for Period 2—2010 to 2017, and 768 for Period 3—2018 to 2020. Median OS in the whole cohort was 11.1, 15.5, and 16.2 months, respectively. Median OS for patients with NSCLC or SCLC was 11.2, 17.2, and 18.2 months, or 10.9, 11.7, and 11.2 months, respectively. The two-year conditional survival was more favorable for NSCLC than SCLC patients. Outcomes were statistically higher for women as compared to men in all periods and all subgroups. Survival of patients with metastatic lung cancer has improved over the past 20 years, mostly in NSCLC, along with the implementation of novel treatment strategies.
Keywords:
lung cancer; survival; Institut Curie; real-life data
